Literature DB >> 27533707

Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

Tara C White-Adams1, Christopher J Ng1, Paula M Jacobi2, Sandra L Haberichter3, Jorge A Di Paola4.   

Abstract

Type 1 von Willebrand disease (VWD) is characterized by low plasma levels of von Willebrand factor (VWF) and clinical bleeding. Several mechanisms have been described that cause a decrease in plasma VWF levels in VWD, and the goal of this study was to elucidate the pathogenic origins of VWD for a group of mutations in the VWF D'D3 region traditionally associated with type 1 VWD. Varying ratios of mutant-to-wild-type VWF were expressed in two cell lines in order to study the intracellular location, multimer assembly, secretion and function of VWF. We identified four mutants (M771I, Y1146C, T1156M, R782Q) that caused defective intracellular packaging and markedly reduced VWF secretion. Consistent with previous reports, Y1146C and T1156M VWF led to a loss of high molecular weight multimers. In a functional analysis, Y1146C demonstrated a novel FVIII binding defect. Mutations R924W and I1094T were processed normally and did not show abnormal FVIII binding suggesting that other mechanisms such as plasma clearance or platelet binding defects may contribute to the pathogenicity of these mutants.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D′D3 domain; Quantitative von Willebrand disease; Von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 27533707      PMCID: PMC5951169          DOI: 10.1016/j.thromres.2016.08.009

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  25 in total

1.  A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.

Authors:  Reinhard Schneppenheim; Jan Jacques Michiels; Tobias Obser; Florian Oyen; Antje Pieconka; Sonja Schneppenheim; Kerstin Will; Barbara Zieger; Ulrich Budde
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

2.  Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Authors:  J Eikenboom; L Hilbert; A S Ribba; A Hommais; D Habart; S Messenger; A Al-Buhairan; A Guilliatt; W Lester; C Mazurier; D Meyer; E Fressinaud; U Budde; K Will; R Schneppenheim; T Obser; O Marggraf; E Eckert; G Castaman; F Rodeghiero; A B Federici; J Batlle; J Goudemand; J Ingerslev; S Lethagen; F Hill; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

3.  von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation.

Authors:  T Mayadas; D D Wagner; P J Simpson
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

Review 4.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

5.  The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF.

Authors:  Jonathan B Rosenberg; Sandra L Haberichter; Mary A Jozwiak; Elizabeth A Vokac; Philip A Kroner; Scot A Fahs; Yohko Kawai; Robert R Montgomery
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

7.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

8.  Effects of the mutant von Willebrand factor gene in von Willebrand disease.

Authors:  Z Zhang; M Lindstedt; M Blombäck; M Anvret
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

9.  The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.

Authors:  P A Kroner; P A Foster; S A Fahs; R R Montgomery
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

Review 10.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  7 in total

1.  Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels.

Authors:  Christopher J Ng; Alice Liu; Sujatha Venkataraman; Katrina J Ashworth; Christopher D Baker; Rebecca O'Rourke; Rajeev Vibhakar; Kenneth L Jones; Jorge Di Paola
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

2.  Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.

Authors:  M Lehmann; K Ashworth; M Manco-Johnson; J Di Paola; K B Neeves; C J Ng
Journal:  J Thromb Haemost       Date:  2017-11-23       Impact factor: 5.824

3.  Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13).

Authors:  Maria Bortot; Katrina Ashworth; Alireza Sharifi; Faye Walker; Nathan C Crawford; Keith B Neeves; David Bark; Jorge Di Paola
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-11       Impact factor: 10.514

4.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

5.  Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Authors:  Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi
Journal:  Blood Adv       Date:  2021-08-10

6.  Advancing multimer analysis of von Willebrand factor by single-molecule AFM imaging.

Authors:  Achim Löf; Gesa König; Sonja Schneppenheim; Reinhard Schneppenheim; Martin Benoit; Ulrich Budde; Jochen P Müller; Maria A Brehm
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

7.  Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity.

Authors:  Christopher J Ng; Keith R McCrae; Katrina Ashworth; Lucas J Sosa; Venkaiah Betapudi; Marilyn J Manco-Johnson; Alice Liu; Jing-Fei Dong; Dominic Chung; Tara C White-Adams; José A López; Jorge Di Paola
Journal:  Res Pract Thromb Haemost       Date:  2018-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.